

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

e application of:

Fernando BAZAN, et al.

Application No.: 10/601,105

Filed: June 20, 2003

For: MAMMALIAN CYTOKINES;

**RELATED REAGENTS AND** 

**METHODS** 

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Examiner: Unassigned

Art Unit: Unassigned

Conf. No.: Unassigned

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on \_\_7-[8-03\_\_\_\_

bv:

MELANIE LYONS

## **INFORMATION DISCLOSURE STATEMENT**

Sir:

The materials as listed in the attached form PTO/SB/08A are brought to the Examiner's attention pursuant to the duty of disclosure under 37 C.F.R. § 1.56, § 1.97, and § 1.98.

All references listed on the attached form PTO/SB/08A have been previously cited either by Applicants or the Examiner in the parent application, U.S. Patent Application No. 09/963,347, filing date September 25, 2001, and copies should be available there. As such, these references will not be provided absent a specific request.

Citation of these documents should not be construed as a representation that the documents are in fact material or are in fact prior art with respect to the instant invention. The Examiner should not make any inference relating to the relative pertinence of cited references based upon the order in which the art is presented. Citation of these documents should not be construed as a representation that a search has been made or that more pertinent art may not be in existence.

Applicants request that the Examiner fully consider the art cited in the attached PTO/SB/08A form. Applicants further request that the Patent and Trademark Office list all such art on the front of any patent issuing from this application.

Applicants believe no fee is required for filing this document; however, if such a fee is required, the Commissioner is hereby authorized to charge DNAX Research Institute Deposit account no. 04-1239.

Respectfully submitted,

Date: <u>18-July 200</u>

Sheela Mohan-Peterson

Reg. No. 41,201

Attorney for Applicants

Customer No. 028008 DNAX Research, Inc. 901 California Avenue

Palo Alto, CA 94304-1104

Telephone (Switchboard): (650) 496-6400 Telephone No. (Direct): (650) 496-1244

Facsimile No.: (650) 496-1200

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Und

Jildel tile (	aperwork Reduction a	CLOITS	393, no persons are required	to respond to a collection of fine	initiation unless it displays a valid Olvib control number	
Substitute of transport 9/PTO				Complete if Known		
			ect cettee	Application Number	10/601,105	
			SCLOSURE	Filing Date	June 20, 2003	
(Use as many sheets as necessary)				First Named Inventor	Fernando BAZAN	
				Art Unit	Unassigned	
				Examiner Name	Unassigned	
Sheet	1	of	2	Attorney Docket Number	DX0903K1B	

Attorney Docket Number

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite	DOCUMENT NUMBER  Number-Kind Code <sup>2 (if known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear		
	No. <sup>1</sup>			. Applicant of Cited Document			
	AA	US-5,965,122	10-12-99	A. Namen, et al.			
		US-		·			
		US-					
		US-					
		US-		·			
		US-					
		US-					
		US-	-				
		US-					
		US-					
		US-					
		US-					
		US-					
	,	US-					

FOREIGN PATENT DOCUMENTS						
Examiner	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear	
Initials*		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5 (if known)</sup>				Τ°
	AB	0314415A2	05-03-89	EPO		
	AC	WO 00/29581	05-25-00	PCT		Х
	AD	WO 00/39149 `	07-06-00	PCT		Х
			-			_

Examiner	·	Date	
Signature	1.	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPOT to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPOT. Time will vary depending upon the individual case. Any comments on the amount of time voul.

preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (04-03) Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Complete if Known Substitute for form 1449/PTO 10/601,105 **Application Number** INFORMATION DISCLOSURE June 20, 2003 Filing Date STATEMENT BY APPLICANT Fernando BAZAN First Named Inventor Art Unit Unassigned (Use as many sheets as necessary) Unassigned **Examiner Name** 2 DX0903K1B 2 Sheet Attorney Docket Number

<u></u>		NON PATENT LITERATURE DOCUMENTS	, · · · · · · · · · · · · · · · · · · ·			
Examiner Initials*	Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	AE	FRIEND, Sherree Lee, et al., Experimental Hematology, "A thymic stromal cell line supports in vitro development of surface IgM+ B cells and produces a novel growth factor affecting B and T lineage cells" (1994), pp. 321-328, Vol. 3.				
	AF	LEVIN, Steven D., et al., <u>Journal of Immunology</u> , "Thymic Stromal Lymphoprotein: A cytokine that promotes the development of IgM+ B cells in Vitro and Signals via a novel mechanism," (January 1999), pp. 677-683, Vol. 162.				
	AG	MAHAIRAS, G.G., et al., GenBank, Accession Number AQ781833, (August 2, 1999), Definition: "HS_3148_A2_C03_T7C CIT Approved Human Genomic Sperm Library D Homo sapiens genomic clone Plate=3148 Col=6 Row=E, genomic survey sequence."				
	АН	MAEURER, Markus J., et al., The Cytokine Handbook, 3rd ed., "Interleukin-7," (1998), Ch. 9:229-269. Thomson, ed.(Academic Press, Inc., San Diego, California).				
	AI	MARRA, M., et al., GenBank, Accession Number AA717930, (December 29, 1997), Definition: "vt09f05.r1 Barstead mouse myotubes MPLRB5 Mus musculus cDNA clone IMAGE: 1162593 5', mRNA sequence."				
	AJ	MARRA, M., et al., GenBank, Accession Number Al591430, (April 21, 1999), Definition: "vt09f05.r1 Barstead mouse myotubes MPLRB5 Mus musculus cDNA clone IMAGE: 1162593 5', mRNA sequence."				
	AK	NCI-CGAP. GenBank, Accession Number AA889581, (January 4, 1999), Definition: "ak25a11.sl Soares_testis_NHT Homo sapiens cDNA clone IMAGE: 14072603', mRNA sequence."				
-						
<u> </u>						

Examiner Signature		Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

EXAMINER: Initial if reterence considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231. Washington, DC 20231.